The company expired its plan on February 23, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | -4.68% | +6.42% | +6.42% |
20/05 | Barclays Adjusts Price Target on GoodRx to $10 From $9, Maintains Overweight Rating | MT |
17/05 | UBS Adjusts Price Target on GoodRx Holdings to $9 From $8, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.42% | 2.68B | |
+31.62% | 276B | |
+5.00% | 135B | |
+30.81% | 94.76B | |
+7.51% | 92.92B | |
+64.02% | 61.13B | |
+15.24% | 46.6B | |
+25.78% | 38.08B | |
+0.15% | 35.74B | |
+15.12% | 29.13B |
- Stock Market
- Equities
- GDRX Stock
- News GoodRx Holdings, Inc.
- GoodRx Holdings, Inc.'s Equity Buyback announced on February 28, 2022, has expired.